Vitrolife AB (LTS:0YAY)

kr 219.5 0 (0%) Market Cap: 29.50 Bil Enterprise Value: 30.63 Bil PE Ratio: 0 PB Ratio: 2.25 GF Score: 90/100

Q1 2024 Vitrolife AB Earnings Call Transcript
Apr 18, 2024

kr167.05 (-8.14%)

Earnings
Vitrolife AB Capital Markets Day Transcript
Dec 12, 2023
Q3 2023 Vitrolife AB Earnings Call Transcript
Oct 27, 2023

kr127.25 (-6.71%)

Earnings
Q2 2023 Vitrolife AB Earnings Call Transcript
Jul 14, 2023

kr174.8 (-18.89%)

Earnings
Q1 2023 Vitrolife AB Earnings Call Transcript
Apr 21, 2023

kr210.15 (+4.16%)

Earnings
Q4 2022 Vitrolife AB Earnings Call Transcript
Feb 02, 2023

kr263.5 (+13.38%)

Earnings
Q3 2022 Vitrolife AB Earnings Call Transcript
Oct 27, 2022

kr177.35 (+6.71%)

Earnings
Q2 2022 Vitrolife AB Earnings Call Transcript
Jul 15, 2022

kr280.8 (+15.22%)

Earnings
Q1 2022 Vitrolife AB Earnings Call Transcript
Apr 22, 2022

kr251.3 (-18.01%)

Earnings
Q4 2021 Vitrolife AB Earnings Call Transcript
Feb 16, 2022

kr322.5 (-17.37%)

Earnings
Q3 2021 Vitrolife AB Earnings Call Transcript
Oct 29, 2021

kr565.25 (+2.68%)

Earnings
Q2 2021 Vitrolife AB Earnings Call Transcript
Jul 15, 2021

kr440.4 (+4.14%)

Earnings
Vitrolife AB Acquires Igenomix SL- Conference Call Transcript
Jul 09, 2021
Q1 2021 Vitrolife AB Earnings Call Transcript
Apr 22, 2021

kr303.1 (+10.14%)

Earnings
Q4 2020 Vitrolife AB Earnings Call Transcript
Feb 10, 2021

kr268.8 (+14.53%)

Earnings
Q3 2020 Vitrolife AB Earnings Call Transcript
Nov 06, 2020

kr218.2 (-2.42%)

Earnings
Q2 2020 Vitrolife AB Earnings Call Transcript
Jul 13, 2020

kr205.4 (-8.30%)

Earnings
Q1 2020 Vitrolife AB Earnings Call Transcript
Apr 23, 2020

kr182.9 (+2.32%)

Earnings
Q4 2019 Vitrolife AB Earnings Call Transcript
Feb 06, 2020

kr196 (-5.81%)

Earnings
Q3 2019 Vitrolife AB Earnings Call Transcript
Nov 06, 2019

kr201.65 (+27.87%)

Earnings
Q2 2019 Vitrolife AB Earnings Call Transcript
Jul 12, 2019

kr198.45 (+11.65%)

Earnings
Q1 2019 Vitrolife AB Earnings Call Transcript
Apr 23, 2019

kr197.3 (-8.95%)

Earnings

Q4 2022 Vitrolife AB Earnings Call Transcript

Feb 02, 2023 / 09:00AM GMT

Release Date Price: kr263.5 (+13.38%)

Transcript

Thomas Axelsson;publ;President;CEO

Vitrolife AB

()-&

Good morning, and welcome to Vitrolife fourth quarter and full year report. Today is the 2nd of February 2023. The speakers of today will be my colleague, CFO, Patrik Tolf; and myself, Thomas Axelsson.

And by that, let's go into the presentation and next page, Page #2. The headline for this presentation is strong profitable growth for the quarter. What we will do is that we will quickly go through the numbers, and then we'll go into more details by Patrick and myself.

So a quick one regarding the quarter is that we had an increase of 66% in Swedish currency, and the sales was SEK 855 million. It was a growth of 11% in local currency. Later on, we will go more into those kind of details. The adjusted gross margin was 56.5%. EBITDA, we made SEK 273 million, and the margin was 31.9%. EBITDA per share SEK 2.02, and operating cash flow of SEK 166 million.

Since it is also the full year report, I will like to also reflect a little bit about the full year report. And that is the

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.